Erleada (apalutamide) is used for the treatment of metastatic castration-sensitive prostate cancer and non-metastatic castration-resistant prostate cancer.

Metastatic castration-sensitive prostate cancer (mCSPC) refers to prostate cancer that still responds to androgen deprivation therapy (ADT) and has spread to other parts of the body.

Non-metastatic castration-resistant prostate cancer (NM-CRPC) refers to prostate cancer that no longer responds to androgen deprivation therapy (ADT) or surgical treatments that lower testosterone, but has not yet been discovered in other parts of the body.

Erleada is an androgen receptor inhibitor. It works by blocking the effect of androgens on the tumor. Androgens, such as testosterone, can promote tumor growth.

Erleada is taken orally, once daily, with or without food.